20-F: NewGenIvf Group Limited Files 20-F Report Following Business Combination

Sentiment:

Shell Company Report 9 April 2024 5:15 PM

NewGenIvf Group Limited files its 20-F report, detailing the completion of its business combination and providing information on its operations and financial condition.

Capital raiseASCA agreed to issue and sell to the Buyers, in a private placement, an aggregate of up to $3,500,000 principal amount of convertible notes (the Notes), consisting of one or more tranches: (i) an initial tranche (the Initial Tranche) of an aggregate principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500, and (ii) subsequent tranches of an aggregate principal amount of Notes of up to $1,750,000 and including an original issue discount of up to aggregate $122,500.As of the date of this Report, an aggregate principal amount of Notes of $2,000,000 were issued and sold to JAK.

Summary

NewGenIvf Group Limited filed a Shell Company Report on Form 20-F.
The report follows the consummation of a business combination on April 3, 2024, involving A SPAC I Acquisition Corp., A SPAC I Mini Acquisition Corp., A SPAC I Mini Sub Acquisition Corp., and NewGenIvf Limited.
The business combination was executed in two steps: a reincorporation merger and an acquisition merger, resulting in Legacy NewGenIvf becoming a wholly-owned subsidiary of PubCo.
In connection with the business combination, ASCA issued convertible notes to JAK Opportunities VI LLC, raising up to $3,500,000.
Chardan Capital Markets, LLC received cash, shares, and a percentage of post-closing financings as deferred underwriting commission.
Following the business combination, NewGenIvf Group Limited operates primarily in Asia Pacific countries, offering IVF treatment and surrogacy services.
As of April 3, 2024, the company had 10,149,386 Class A ordinary shares and 8,319,988 warrants outstanding.
The company's principal executive office is located in Bangkok, Thailand.
Onestop Assurance PAC is now the independent auditor of PubCo.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports the completion of a business combination and related transactions. While the completion of the merger is a positive step, the document also highlights potential risks and uncertainties.

Positives

The business combination was successfully completed, establishing NewGenIvf Group Limited as the parent company.
The company secured additional financing through the issuance of convertible notes.
The company has a presence in multiple countries in the Asia Pacific region, providing a diversified service offering.

Risks

The report references risk factors detailed in the Form F-4, including risks related to NewGenIvf's business and industry, and its relationships with third parties.
The company is subject to legal proceedings arising from the normal course of business activities, which can have an adverse impact on the business, financial condition and/or operations.

Future Outlook

The company's future outlook is tied to the risk factors outlined in the Form F-4 and its ability to successfully integrate and grow its business post-merger.

Industry Context

The announcement reflects activity in the fertility services industry, where companies are pursuing growth through mergers and acquisitions to expand their geographic reach and service offerings.

Comparison to Industry Standards

It is difficult to compare the results to global benchmarks without specific financial data in the document.
However, similar companies in the fertility industry include Virtus Health, a leading provider of IVF services in Australia, and Invo Bioscience, which focuses on simpler and more affordable fertility treatments.
The success of NewGenIvf will depend on its ability to compete with these established players and differentiate its services in the Asia Pacific market.

Legal Proceedings

We are currently not a party to any material legal or administrative proceedings.
We have been, and may from time to time be involved in various legal proceedings arising from the normal course of business activities.

Related Party Transactions

Our related party transactions are described in the Form F-4 in the section entitled Certain Relationships and Related Party Transactions which is incorporated by reference herein.

Stakeholder Impact

The business combination and subsequent operations will impact shareholders, employees, customers, suppliers, and creditors.
The success of the combined company will depend on its ability to create value for these stakeholders.

Key Dates

Date	Description
February 15, 2023	Merger Agreement date among ASCA, NewGenIvf Limited, certain shareholders of NewGenIvf Limited, A SPAC I Mini Acquisition Corp., and A SPAC I Mini Sub Acquisition Corp.
January 26, 2023	PubCo was incorporated as a British Virgin Islands business company.
October 27, 2023	PubCo's registration statement on Form F-4 (File No. 333-275208) initially filed with the Securities and Exchange Commission.
March 1, 2024	ASCA entered into an acknowledgement agreement with Chardan Capital Markets, LLC related to the deferred underwriting commission owed to Chardan in connection with ASCAs initial public offering.
March 1, 2024	Shareholders adopted Amended and Restated Memorandum and Articles of Association.
April 3, 2024	PubCo consummated the Business Combination pursuant to the terms of the Merger Agreement and Legacy NewGenIvf became a wholly owned subsidiary of PubCo.
April 3, 2024	Marcum Asia was dismissed as auditors.
May 3, 2024	Warrants will become exercisable.
April 3, 2029	Public Warrants will expire.

Keywords

Business Combination, IVF, Surrogacy, NewGenIvf, Merger, Warrants, Shares, Financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.